Atnahs Pharma’s $350 Million Acquisition of AstraZeneca’s Assets

Latham & Watkins advised Atnahs Pharma in the transaction.

AstraZeneca has agreed to sell the global commercial rights to Inderal (propranolol), Tenormin (atenolol), Tenoretic (atenolol, chlorthalidone fixed-dose combination), Zestril (lisinopril) and Zestoretic (lisinopril, hydrochlorothiazide fixed-dose combination) to Atnahs Pharma (Atnahs).

The agreement excludes the rights in the US and India, which were previously divested, and in Japan, which will be retained by AstraZeneca.

Atnahs will make an upfront payment of US$350 million to AstraZeneca. AstraZeneca may also receive future sales-contingent payments of up to US$40 million between 2020 and 2022.

Latham & Watkins advised Atnahs in the transaction, with a deal team led by London corporate partner Robbie McLaren (Picture), with New York counsel Eliot Choy and London associates Frances Stocks Allen, Emily Cridland, Samantha Peacock, Natalie Brown, and Mihail Krepchev.

Involved fees earner: Natalie Brown – Latham & Watkins; Eliot Choy – Latham & Watkins; Emily Cridland – Latham & Watkins; Mihail Krepchev – Latham & Watkins; Robbie McLaren – Latham & Watkins; Samantha Peacock – Latham & Watkins; Frances Stocks – Latham & Watkins;

Law Firms: Latham & Watkins;

Clients: Atnahs Pharma;